MedTrace Logo

The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients

NCT05680870 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-09-09

No results posted yet for this study

Summary

Oxaliplatin(OXA) chemotherapy protocols are used in treatment of cancers like colorectal (CRC) and pancreatic cancer. OXA causes peripheral neuropathy which is considered treatment limiting factor. In recent studies, it shows that omeprazole(OME) has antioxidant effect and can inhibit organic cation transporter 2 (OCT2) in kidney. So OME can protect against peripheral neuropathy induced by OXA through oxidative stress . Also OME activates extracellular-signal-regulated kinase(ERK) / mitogen activated protein kinase ( MAPK) pathway, so improves demyelinating symptoms.

Conditions

  • Chemotherapy Induced Peripheral Neuropathy

Interventions

DRUG

Omeprazole

Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles

Sponsors & Collaborators

  • Aya Mohamed Sadek Elsaid

    lead OTHER

Principal Investigators

  • Sahar K Hegazy, Professor · Professor of clinical pharmacy , faculty of pharmacy, Tanta university

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-12-05
Completion
2024-12-12

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05680870 on ClinicalTrials.gov